Cardiome Development, a subsidiary of Cardiome Pharma, and Tzamal Medical Group are collaborating to sell and distribute Brinavess (vernakalant intravenous) exclusively in Israel. Tzamal Medical, a private group of companies providing medical devices and equipment for the healthcare industry, has agreed to specific annual commercial goals for Brinavess, which was approved in Europe for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. Financial details of the agreement have not been disclosed.
"This agreement with Tzamal Medical reaffirms Cardiome's commitment to continue making Brinavess available worldwide, including markets outside of Europe," said Karim Lalji, Cardiome's chief commercial officer.
Edi Steinberg, chief executive officer at Tzamal BioPharma, the pharmaceutical arm of Tzamal Medical, said, "Brinavess will be a great addition to our current line of hospital intensive and emergency care drug products. Emergency room physicians and surgeons need additional treatment options for Atrial Fibrillation."
The three years agreement begins September 15.